Dr. Martin Fried recently worked with other members of an interdisciplinary team at OSU to complete an independent review of the FDA's actions and decisions on currently approved opioid prescription medication.
The FDA has released a report based on the group's findings, which include three overarching recommendations. The group calls for prioritization of public health considerations in opioid prescription medication regulatory decision-making; increased collaboration with Congress regarding opioid prescription medication approval and product promotion; and greater transparency in regulatory decision-making connected to opioid prescription medications.